linjc16/ctgov huggingface dataset:
Neuromusculaire Monitoring Survey

Study Overview
=================
Brief Summary
-----------------
This survey aims to better define the willingness-to-buy for Applications in Neuromuscular Monitoring throughout European hospitals.

Detailed Description
-----------------
This study consists of a simple online survey that takes approximately 2 minutes to complete. The study aims to assess the willingness-to-buy for Applications in Neuromuscular Monitoring (monitoring and software-based) within the anesthesia departments of European hospitals. The survey is targeted to the department heads of the questioned anesthesia departments.

Official Title
-----------------
Neuromusculaire Monitoring Survey - Financial

Conditions
-----------------
Survey, Financial

Intervention / Treatment
-----------------
* Other: Survey


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Active Anesthesiology department heads of European Anesthesiology departments. Exclusion Criteria: None
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Survey|Questionnaire to ask about the willingness-to-buy applications in neuromuscular monitoring.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Willingness to buy questionnaire | Would this person be willing to buy neuromuscular monitoring applications. | 4 months |
Evaluation of the 755nm Alexandrite Laser for the Treatment of Tattoos

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to collect further data on the safety and efficacy of removing unwanted non cosmetic tattoos (including recalcitrant) using the 755nm Alexandrite laser.

Official Title
-----------------
Evaluation of the 755nm Alexandrite Laser for the Treatment of Tattoos

Conditions
-----------------
Tattoos

Intervention / Treatment
-----------------
* Device: 755nm Alexandrite Laser
* Device: 755nm Alexandrite Laser with CAP Array


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Is a healthy male or female between 18 and 85 years old. Has unwanted non-cosmetic tattoo(s) and wishes to undergo laser treatments to remove them. Is willing to consent to participate in the study. Is willing to comply with all requirements of the study including being photographed, following post treatment care and attending all treatment and follow up visits Exclusion Criteria: Is hypersensitive to light exposure. Has active localized or systemic infection. Is taking medication(s) for which sunlight is a contraindication. Has a history of squamous cell carcinoma or melanoma. Has a history of keloid scarring. Has used oral isotretinoin (Accutane®) within 12 months of initial treatment or plans on using during the course of the study. Note: Skin must regain its normal degree of moisture prior to treatment. Has a history of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or use of immunosuppressive medications. Is female and pregnant, has been pregnant within the last 3 months, is currently breast feeding or planning a pregnancy during the study period. Is allergic to lidocaine, tetracaine or Xylocaine with epinephrine. Has any other reason determined by the physician to be ineligible to participate in the study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 755nm Alexandrite Laser<br>755nm Alexandrite Laser | Device: 755nm Alexandrite Laser<br>* 755nm Alexandrite Laser<br>Device: 755nm Alexandrite Laser with CAP Array<br>* 755nm Alexandrite Laser with CAP Array<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tattoo Clearance Using Photographic Evaluation | 2D photography comparing pre and post treatment photos, where the percentage of tattoo clearance between the photos was determined by the evaluator. | up to 3 months post last treatment |
Feasibility of Smartphone-based Measurement on Badminton Footwork

Study Overview
=================
Brief Summary
-----------------
To evaluate the feasibility of a smartphone-based measurement on badminton footwork. The performance of footwork will be collected utilizing a smartphone app and further investigate the validity, reliability and discrimination of the measurement.

Official Title
-----------------
Feasibility of Smartphone-based Measurement on Badminton Footwork

Conditions
-----------------
Sports Physical Therapy

Intervention / Treatment
-----------------
* Other: footwork


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adults familiar with badminton six points foot work.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| fast group<br> | Other: footwork<br>* six-point footwork<br>|
| slow group<br> | Other: footwork<br>* six-point footwork<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| inertial data of footwork performance | the inertial data collected from both smartphone and IMU sensor during footwork performance. Second assessment was delivered a week after the first assessment | a week |
Circulating Extracellular Exosomal Small RNA as Potential Biomarker for Human Pancreatic Cancer

Study Overview
=================
Brief Summary
-----------------
This study is for the verification of biomarkers for pancreatic cancer treatment using small RNA liquid biopsy, combined with EUS-FNA tissues.

Detailed Description
-----------------
CA19-9 is the FDA approved biomarker for the diagnosis of pancreatic cancer. However, the specificity of CA19-9 to differentiate between pancreatic cancer, cholangiocarcinoma, or other pancreatic lesions is not satisfying enough. Tumor cells secret abundant exosomes in the early stage. Circulating tumor cells are detected mainly in the advanced stage. Meanwhile, the role of non-coding RNA draws more and more attention in tumor area. Exosomes protect inside RNA from plasma RNase. Compared with long RNA, small RNA, including miRNA, snoRNA, tRNA, piRNA could exist more stably. By means of next-generation sequencing, we look forward to finding new exosomal small RNA biomarkers.

Official Title
-----------------
Diagnostic and Prognostic Values of EUS-FNA Specimens and Circulating Exosomal Small RNA in Patients With Pancreatic Cancer

Conditions
-----------------
Pancreas Adenocarcinoma

Intervention / Treatment
-----------------
* Procedure: Venous sampling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age >18 pancreatic cancer patients pancreatic lesions other than PAAD chronic pancreatitis cholangiocarcinoma Exclusion Criteria: diagnosed with other pathological types of cancer treated with chemo/radio/surgery previously

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: pancreatic cancer group<br>pancreatic cancer, anticipated participants: 68 other pancreatic lesions including MCN, SCN, IPMN, SPN without malignant pathological finding chronic pancreatitis cholangiocarcinoma healthy control anticipated participants: 34 | Procedure: Venous sampling<br>* venous sampling of 12ml<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| senstivity | sensitivity of exo-sRNA | up to 8 weeks | 
| specificity | specificity of exo-sRNA to differentiate between PAAD and other benigh or malignant pancreatic occupying lesions | up to 8 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| survival time | relationship between expression level of chosen exosomal RNA and patients' survival time in PAAD group | up to 18 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
exosome, snoRNA, endoscopic ultrasound, liquid biopsy
PerClot to Control Bleeding in Endoscopic Sinus Surgery

Study Overview
=================
Brief Summary
-----------------
A prospective, single centre, single arm study designed to collect clinical data on PerClot when used in subjects undergoing endoscopic sinus surgery.

Official Title
-----------------
A Post Market Surveillance Study Evaluating the Safety and Effectiveness of PerClot to Control Mild Bleeding in Subjects Undergoing Endoscopic Sinus Surgery

Conditions
-----------------
Sinusitis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects having Endoscopic Sinus Surgery Subjects who will have PerClot used as a haemostatic agent Subjects willing and able to give consent Subjects over 18 years old Exclusion Criteria: Subjects unable or unwilling to give consent for their data to be collected

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of subjects who achieve of haemostasis after the application of PerClot |  | intraoperatively | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of subjects who require the use of alternative methods to achieve haemostasis after the application of PerClot |  | intraoperatively |
Anti-Mullerian Hormone Levels Before and After an Open Myomectomy

Study Overview
=================
Brief Summary
-----------------
Anti-Mullerian hormone (AMH) is a marker for ovarian reserve. It is well known that ovarian surgery for endometriosis lowers Anti-Mullerian hormone, but little is known for other surgeries. We seek to investigate the hormone variations before and after an open myomectomy. Hypothesis: Anti-Mullerian hormone levels drop following surgery but return to normal levels in a few months

Official Title
-----------------
Anti-Mullerian Hormone Levels Variations Following an Open Myomectomy

Conditions
-----------------
Anti-Mullerian Hormone

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 to 42 years old Requiring open myomectomy for any indication Exclusion Criteria: Incapable of informed consent Use of hormonal contraception or Gonadotropin-releasing hormone agonists in the past 3 months Woman over 42 years old Post-menopause women Positive B-human chorionic gonadotropin the day of surgery Ovarian surgery (at the same time) Pre-operative AMH below 0.3 ng/mL

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 42 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Open myomectomy<br>All patients belong to the same group Description includes the surgical technique | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Anti-Mullerian Hormone levels variation | Anti-Mullerian Hormone levels before and 6 months after surgery | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Anti-Mullerian hormone, Myomectomy, Laparotomy
Trial Comparing Mini-Arc Precise Pro and the Trans Vaginal Obturator Tape for Stress Urinary Incontinence

Study Overview
=================
Brief Summary
-----------------
Randomized comparison of two surgeries for the treatment of female stress urinary incontinence.

Official Title
-----------------
Randomized Clinical Trial Comparing Mini-Arc Precise Pro and the Trans Vaginal Obturator Tape for Surgical Management of Stress Urinary Incontinence

Conditions
-----------------
Stress Urinary Incontinence, Urethral Sling Surgery

Intervention / Treatment
-----------------
* Device: Mini Arc Precise Pro and Trans vaginal obturator sling (TVT-0)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: women with stress urinary incontinence with a positive cough test patient request surgery for treatment Exclusion Criteria: prodominantely overactive bladder previous failed procedure MUCP <20 cm H2O presence of vaginal prolapse > stage 1 voiding dysfunction (PVR>100 mL)

Ages Eligible for Study
-----------------
Minimum Age: 25 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Precise sling vs TVT-O sling<br> | Device: Mini Arc Precise Pro and Trans vaginal obturator sling (TVT-0)<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cough test at one year from surgery |  | One year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Subjective symptoms, QOL questionaires |  | 1 & 2 years post surgery |
Ultrasound Based Acoustic Radiation Force Impulse Imaging

Study Overview
=================
Brief Summary
-----------------
ARFI (Ultrasound-based Acoustic Radiation Force Impulse) will be used during ultrasound guided needle biopsy of the liver of children.

Detailed Description
-----------------
A new technique based on ultrasound, known as Acoustic Radiation Force Impulse (ARFI) imaging is performed using standard approved ultrasound machines and transducers. The sound waves or impulses are generated in a different pattern and offer information on the stiffness of the tissue. This new technique will be evaluated for usefulness in diagnosing different liver conditions.

Official Title
-----------------
Ultrasound Based Acoustic Radiation Force Impulse, Shear Wave Velocity Imaging in Pediatric Patients Undergoing Liver Biopsy

Conditions
-----------------
Liver Fibrosis, Liver Inflammation

Intervention / Treatment
-----------------
* Device: Ultrasound-Based Acoustic Radiation Force Impulse (ARFI)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years of age or younger Scheduled to have a needle biopsy of the liver at C.S. Mott Children's Hospital or Dept. of Radiology at the Univ. of Michigan Hospital Scheduled to have an abdominal ultrasound to evaluate your liver (with no known liver disease) Exclusion Criteria: None to list

Ages Eligible for Study
-----------------
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Ultrasound-based Acoustic Radiation Force Imaging<br>The liver was scanned using ultrasound and ultrasound-based acoustic radiation force impulse imaging technique (ARFI). | Device: Ultrasound-Based Acoustic Radiation Force Impulse (ARFI)<br>* Research scans using ultrasound-based acoustic radiation force impulse (ARFI) will image the liver non-invasively.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ARFI/VTQ and ARFI/VTIQ Liver Shear Wave Speed vs. Liver Histologic Fibrosis Score | Tissue shear wave speed is positively correlated to a material's/tissue's stiffness and can be noninvasively measured by ultrasound. The relationship between liver shear wave speed and liver histologic fibrosis score were assessed using 2 different ultrasound methods. Liver shear wave speed as obtained using 2 different ultrasound methods served as our primary outcome measures. Note, the histologic scoring system (Ishak) ranged from 0 to 6, where 0 = no fibrosis and 6 = cirrhosis. | 10 minutes |
A Study to Collect Blood Samples From Patients With Spinal Muscular Atrophy for Biomarker Analysis

Study Overview
=================
Brief Summary
-----------------
In this single center study blood samples for biomarker analysis will be collected from patients with spinal muscular atrophy. Up to 21 mL blood will be drawn from eligible patients at a single visit.

Official Title
-----------------
A Single Center Study to Collect Samples From SMA Patients for Biomarker Analysis

Conditions
-----------------
Muscular Atrophy, Spinal

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Self-identified as 5q-autosomal recessive spinal muscular atrophy (SMA) type I, II or III as judged by their neurologist upon diagnosis Ability and willingness to provide blood samples Willingness (by the patient or patient's parents or legal guardian) to complete to their best ability a questionnaire which requests specific clinical and genetic information Able to participate and willing to give written informed consent or assent. Informed consent will be obtained from the patient, or the patient's parent or legal guardian. Exclusion Criteria: Any known genetic condition other than spinal muscular atrophy, unless it is not interfering with the purpose of this study based on the Sponsor's judgment Participation in a clinical trial (except observational studies) within the previous 14 days Donation of blood or significant blood loss within three months prior to screening Concomitant disease or condition that could interfere with, or treatment of which might interfere with, the conduct of this study, or that would, in the opinion of the investigator, pose an unacceptable risk to the patient in this study
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cohort<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| SMN1/SMN2 detection in blood by mRNA assay |  | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| SMN protein level in blood/lymphocytes |  | 1 day |
Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia

Study Overview
=================
Brief Summary
-----------------
This study will further evaluate if AMN107 is safe in adults with chronic myeloid leukemia who are resistant or intolerant to imatinib and to provide patients access to this new drug until the drug becomes commercially available.

Official Title
-----------------
An Open-label, Multicenter, Expanded Access Study of Oral AMN107 in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase, or Chronic Phase.

Conditions
-----------------
Chronic Myeloid Leukemia

Intervention / Treatment
-----------------
* Drug: AMN107


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Imatinib-resistant or -intolerant Philadelphia chromosome-positive chronic myeloid leukemia in blast crisis, accelerated phase, or chronic phase. Chronic myeloid leukemia patients who have been treated with an investigational tyrosine kinase inhibitor. Laboratory values within normal limits. Exclusion criteria: Impaired cardiac function. Acute or chronic liver or renal disease considered unrelated to tumor. Other concurrent severe and/or uncontrolled medical conditions (e.g., uncontrolled diabetes, active or uncontrolled infection) that could cause unacceptable safety risks or compromise compliance with the protocol. Patients who are currently receiving treatment with any of the medications that have the potential to prolong the QT interval or to inhibit the metabolism of AMN107 (CYP3A4/5 inhibitors). Patients with a history of another malignancy that is currently clinically significant or currently requires active intervention. Other protocol-defined inclusion/exclusion criteria may apply.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: AMN107|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Chronic myeloid leukemia, AMN 107, Imatinib resistant or intolerant, nilotinib, enact